GlassScriptPhysician profile
Amanda C Miller
NPI 1245642537
$3,360.47
in general payments reported to CMS, 2019-2025
31 companies · $677 in 2025
The $677 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $452 · 2021: $423 · 2022: $470 · 2023: $197 · 2024: $795 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,493 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,492.89 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $516.37 | 2021-2025 | |
| Lilly USA, LLC | $389.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $328.56 | 2019-2025 | |
| Novo Nordisk INC | $319.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $290.78 | 2019-2024 | Repatha, Otezla |
| Astellas Pharma US INC | $242.98 | 2023-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.88 | 2021-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $117.19 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.33 | 2019-2021 | |
| Neos Therapeutics, LP | $98.94 | 2021-2024 | Adzenys Xr-Odt |
| Astrazeneca Pharmaceuticals LP | $71.99 | 2020-2022 | |
| Sanofi Pasteur INC. | $69.36 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $67.23 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $58.20 | 2020-2025 | Spravato |
| Merck Sharp & Dohme LLC | $49.58 | 2024-2025 | Capvaxive, Vaxneuvance, Gardasil 9 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $48.17 | 2025 | Flucelvax, Fluad |
| Abbott Laboratories | $45.65 | 2024-2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $45.47 | 2020-2021 | |
| Amarin Pharma, INC. | $43.93 | 2020-2021 | |
| Hologic Sales and Service, LLC | $43.47 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Dexcom, INC. | $41.70 | 2021-2024 | Dexcom G6 Transmitter |
| Eisai INC. | $39.40 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.54 | 2022 | |
| Boston Scientific Corporation | $23.45 | 2025 | Watchman Flx |
| Axsome Therapeutics, INC. | $20.31 | 2023 | Auvelity |
| Roche Diagnostics Corporation | $17.33 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.09 | 2022 | |
| Avanir Pharmaceuticals, INC. | $14.31 | 2019 | |
| Insulet Corporation | $13.99 | 2025 | Omnipod |
| Glaxosmithkline, LLC. | $13.13 | 2023 | Shingrix |
| Novartis Pharmaceuticals Corporation | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.